
FDA Grants Fast Track Designation to ZL-1310 in Small Cell Lung Cancer
The United States Food and Drug Administration (FDA) has granted fast track designation to ZL-1310 for the treatment of extensive-stage small cell lung cancer, according to a news release from Zai Lab. Fast track designation helps speed the development and …